STK11 and non-small cell lung carcinoma: As GAS6/AXL was demonstrated to have a broad effect on the immune TME, which facilitates an immunosuppressive TME, bemcentinib (R428/BGB324) has been granted fast track designation by the U.S. Food and Drug Administration in STK11-mutated advanced metastatic NSCLC patients that have a suboptimal response to immune checkpoint blockade (NCT03184571) 60.